Connecticut Cannabis Company Sold to Tuatara Capital
Tuatara Capital didn’t travel far to find its latest investment. While several companies recently have targeted Florida medical cannabis growers (and their licenses), the New York City-based cannabis investor took a drive up I95 to bag Connecticut Pharmaceutical Solutions (CTS). CTS is a licensed medical cannabis cultivator in the state of Connecticut. It manufactures pharmaceutical-grade medical cannabis products, including dried flower, extracted concentrates, vaporizers, tinctures, oral tablets and sprays, and topical treatments. Tuatara Capital is a specialized alternative investment manager founded in 2014 to support the legal cannabis industry. It currently manages more than... Read More »
PaxVax Changes Hands Again
Specialty vaccine maker PaxVax Inc. has changed owners again, more than doubling its equity value in two and a half years. The Redwood City, California-based company was acquired by Cerberus Capital Management in December 2015 for $105 million from Ignition Growth Capital and other investors. The sellers retained a minority stake, while Cerberus took the majority. In August, the company was sold to Emergent BioSolutions Inc. (NYSE: EBS), which develops and commercializes specialty products for use in biodefense and commercial markets. Emergent paid $270 million, 3.4x revenue, based on statements that the target’s 2019 revenues are expected to be between $70 million and $90 million.... Read More »
Buyers Flock to Pharmaceuticals, Again
Pharmaceutical deal activity made a comeback in the second quarter of 2018, with 41 transactions reported, and counting. That is the highest quarterly haul in two years, but what happened to dealmaking in the intervening period? Deal volume dropped off soon after the 2016 presidential election, as companies and investors waited for President Trump’s promised tax overhaul. That legislation came in December 2017, and activity in this sector has picked up accordingly. In fact, the second quarter’s deal volume was 64% greater than that of the first quarter, and 156% better than what was reported in the second quarter of 2017, the sector’s nadir. One of those transactions was a record-breaking... Read More »
The Power of the FDA
What happens when the FDA rejects not one drug application, but two, in a short period of time? Your share price plunges by nearly 90%. And then you look for options. Such was the dilemma faced by UK-based drug maker Vernalis plc. So, last March the Vernalis board started looking for offers to buy the company. One attraction was that it had close to $34 million of cash that would be at the disposal of a buyer. Publicly traded Ligand Pharmaceuticals emerged as the buyer, paying about $42 million, or a 45.7% premium to the closing price the day before the sales process was announced in March. It was just a 1.7% premium to the volume weighted average price for the three months before the... Read More »
Dermatology Drug Portfolios Trade Hands
Dermatology physician practics are all the rage among private equity groups these days. Thirty deals targeting this specialty have been announced in the first seven months of 2018. All have been acquired by a private equity firm or one of their platform companies. But in the first week of August, two international pharmaceutical companies acquired portfolios of dermatology brands from the likes of Allergan plc (NYSE: AGN) and Bayer AG (BAYGn.DE). Barcelona-based Almirall, S.A. (MCE: ALM) was the only company to disclose a price in its announcement. It agreed to pay $550 million upfront for Allergan’s U.S. dermatology portfolio, and a possible earn-out of up to $100 million based on... Read More »Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
